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Purpose: To evaluate total antioxidant status (TAS) in the plasma of pseudoexfoliation glaucoma (PEG) patients and to
compare this level with a matching control group. Additionally, we aim to investigate the effect of the combined action
of the lysyl oxidase-like 1 (LOXL1) mutation status with TAS level on the development of PEG.
Methods: Plasma samples were obtained from 54 PEG patients and 54 controls of matching age, sex, and ethnicity. TAS
in all samples was determined by spectrophotometric and enzyme-linked immunosorbent assay methods. The coding
region of LOXL1, where it encompasses both single nucleotide polymorphisms (SNPs; rs1048661 and rs3825942), was
sequenced.
Results: The mean (±SD) total antioxidant (TAS) value was lower among patients: 0.87 (0.24), range 0.9–1.41 than
controls: 1.07 (0.23), range 0.72–1.94, and this difference was statistically significant (p<0.0001: 95%CI: −0.295–0.114).
Evaluating the impact of age, sex, and the mutation in addition to the mean TAS value in patients with PEG, a logistic
regression analysis was conducted using diseased/not diseased as the outcome of interest (the dependent variable). Results
show that, controlling for all other variables, mean TAS value (p<0.0001) and the mutation G/G in rs3825942 (p=0.041)
are significant risk factors for PEG.
Conclusions: Our findings provide evidence that TAS decreases in the plasma of PEG patients, suggesting that TAS may
have an important role in the pathogenesis of PEG. The combined effect of the “G” allele and the decreased TAS may
contribute to the overall pathogenesis of PEG.
It has been demonstrated that oxidative DNA damage is
significantly greater in the trabecular meshwork (TM) cells of
glaucoma patients compared to controls [1]. Moreover, in
vivo  studies  in  humans  have  shown  that  both  intraocular
pressure  (IOP)  increase  and  visual  field  damage  are
significantly related to the amount of oxidative DNA damage
[2]. Similarly, severity of optic nerve damage in eyes with
primary open-angle glaucoma is correlated with changes in
the TM [3]. It has been shown that the retinal ganglion cells
(RGCs), which may die through an apoptotic process, lead to
glaucomatous optic neuropathy [4,5]. In addition to elevated
intraocular  pressure  (IOP)  [6,7],  retinal  ischemia  [8],
nutritional status [9], and oxidative stress have been proposed
as etiologic factors in the pathophysiology of glaucomatous
RGC death [10]. Oxidative stress has been implicated to cause
increased  IOP  by  triggering  TM  degeneration  and  thus
contributing to alterations in the aqueous outflow pathway
[11].  Indeed,  treatment  with  hydrogen  peroxide  (H2O2)
impairs  TM  cell  adhesion  to  the  extracellular  matrix  and
causes  rearrangement  of  cytoskeletal  structures  [11].  In
humans,  in  vivo  experiments  demonstrated  that  oxidative
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DNA damage is significantly more abundant in the TM cells
of glaucoma patients. Additionally, both increased IOP and
visual field damage were significantly related to the amount
of oxidative DNA damage affecting TM cells [11,12]. The
antioxidant  status  of  biologic  samples  is  regarded  as  an
indicator of oxidative stress, and the measurement of total
antioxidant status (TAS) is one of the most commonly used
and useful procedures to test for prediction of oxidative status
[13].  We  previously  investigated  the  presence  of  various
mitochondrial abnormalities in various types of glaucoma and
found  an  evidence  of  mitochondrial  DNA  (mtDNA)
mutations and decreased mitochondrial respiratory activities
[14,15].  Also,  we  found  an  association  between  certain
mtDNA haplogroups and various types of glaucoma [16-18].
Additionally,  we  found  an  association  between  various
glutathione S transferase (GST) gene polymorphisms (coded
for a group of enzymes involved in detoxifying peroxidized
lipids  and  various  harmful  toxins)  and  glaucoma  [19].
Decreased GST function might interfere with the metabolism
of oxidative intermediates and exacerbate the direct or indirect
damaging effects of oxidative stress on the optic nerve. All of
these studies by our group and others point to an oxidative
stress mechanism that contributes to glaucoma pathogenesis
[20].
We have recently shown that the “G” allele frequencies
of both rs1048661 and rs3825942 SNPs of the lysyl oxidase-
like  1  (LOXL1)  gene  differed  between  pseudoexfoliation
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2769glaucoma (PEG) patients and control subjects from Saudi
Arabia (p=0.0056 and p<0.0001, respectively) [21]. These
results  suggest  that  this  gene  may  play  a  role  in  the
development of PEG, but do not answer many remaining
questions  about  the  etiology  of  PEG.  These  results  also
highlight the fact that other genetic causes or risk factors,
either independently or in direct interaction with LOXL1, may
play a role in the development of PEG.
Our  aim  is  to  evaluate  total  antioxidant  levels  in  the
plasma of PEG patients and compare this level with those of
matching controls. Additionally, we will investigate the effect
of the combined action of LOXL1 mutation status and the TAS
level on the development of PEG.
METHODS
Study  population:  The  study  adheres  to  the  tenets  of  the
Declaration  of  Helsinki,  and  all  participants  signed  an
informed consent. The study was approved by the College of
Medicine Ethical Committee (approval number # 08–657).
Saudi Arab participants with clinically diagnosed PEG and
healthy  controls  were  recruited  into  the  study  at  King
Abdulaziz  University  Hospital  (KAUH)  in  Riyadh,  Saudi
Arabia. All participants underwent a standardized detailed
ophthalmic  examination,  which  included  measurement  of
intraocular  pressure  (IOP)  by  Goldmann  applanation
tonometry, slit lamp biomicroscopy, gonioscopy, and dilated
examination of the lens and fundus. Subjects with PEG (n=54)
were defined as those with clinical evidence of exfoliation
material on the pupil margin or anterior lens surface, the
presence of glaucomatous optic neuropathy with associated
visual field loss in one or both eyes, and documented IOP
≥22 mmHg in either eye. Saudi Arab subjects (n=54) with no
evidence  of  pseudoexfoliation  material,  normal  anterior
segments,  healthy  optic  discs,  and  IOP  <18  mmHg  were
recruited as controls.
Plasma  preparation  and  storage:  Blood  samples  were
collected in EDTA (EDTA) tubes. The tubes were centrifuged
at 5,500× g for 5 min. The plasma layer was separated and
stored at −80 °C until use and the buffy layer was used for
DNA extraction.
Plasma total antioxidant status: A widely used colorimetric-
based assay available from Randox (Randox Laboratories
Ltd., Crumlin, UK) was used to evaluate the plasma total
antioxidant  status.  The  assay  involves  brief  incubation  of
ABTS® (2,2’-Azinobis-di[3-ethylbenzthiazoline sulphonate];
Sigma-Aldrich Life Science, St. Louis, MO) with peroxidase
(metmyoglobin)  and  hydrogen  peroxide,  resulting  in  the
generation of ABTS®+ radical cations. The method detects a
reduction in the generation of the ABTS®+ radical cations by
plasma antioxidants, and the decrease in the generation of
ABTS®+  radical  cations  is  proportional  to  their  total
antioxidant  concentration.  The  assay  was  performed  in
duplicate on an automated biochemical analyzer, ChemWell-
T (Awareness Technology Inc., Palm City, FL), as per the
manufacturer’s instructions (Randox Laboratories Ltd.). The
analyzer was programmed using a ChemWell-T Assay Editor
in  the  standard  assay  mode  to  add  200  µl  of  chromogen
(metmyoglobin  and  ABTS®)  and  4  µl  of  plasma  sample/
standard control/distilled water, incubate at 37 °C for 10 s, and
read at 630 nm. This was followed by the addition of 40 µl of
substrate (hydrogen peroxide in stabilized form), incubation
at 37 °C for exactly 3 min, and measuring absorbance at 630
nm.  A  standard  control  (6-hydroxy-2,5,7,8-
tetramethylchroman-2carboxylic  acid)  provided  in  the  kit
(Cat. No. NX 2332: lot specific concentration=2.08 mmol/l)
was used for calibration. The total antioxidant status (TAS)
was expressed as mmol/l.
DNA Analysis: Five ml of peripheral blood was collected in
EDTA tubes from all participating individuals. DNA was
extracted using the illustra blood genomicPrep Mini Spin Kit
from GE Healthcare (Buckinghamshire, UK), and stored at –
20 °C in aliquots until required. PCR amplifications of the
region  encompassing  both  LOXL1  SNPs  (rs1048661  and
rs3825942)  were  performed  using  the  primers  described
previously  [21],  and  presented  in  Table  1.  Successfully
amplified fragments were sequenced in both directions using
M13 forward and reverse primers and the BigDye terminator
v3.1 cycle sequencing kit (Applied Biosystems, Foster City,
CA). Fragments were then run on the 3130xl Genetic Analyzer
(Applied  Biosystems)  according  to  the  manufacturer’s
protocol. All of the sequenced fragments were then analyzed
using SeqScape software v2.6 (Applied Biosystems). Allele
frequencies  for  SNP  rs1048661  and  rs3825942  were
confirmed by repeating the sequencing in both the forward
and reverse directions.
Statistical Analysis: Statistical analysis was performed with
SPSS  version  19.0  (IBM  Corp.,  Armonk,  NY),  MedCalc
version 11.6 (MedCalc Software, Mariakerke, Belgium) and
Statpac  version  11  (StatPac  Inc.,  Bloomington,  MN).
Descriptive  analysis  was  conducted  to  describe  and
understand the sample. Student’s t-test was used to compare
the mean TAS across groups, while the Mann–Whitney U test
was used to compare the mean TAS within groups (between
different genotypes). Binary logistic regression analysis was
performed to estimate the impact and direction of the effect
of  each  risk  factor  on  patients  with  pseudoexfoliation
glaucoma. A p-value of <0.05 was considered of statistical
significance,  while  all  tests  were  supported  by  the
corresponding 95% confidence intervals.
RESULTS
A total of 108 individuals were recruited for this study with
the mean (±SD) age of 67.7 (10.5) years, ranging from (32–
85). The majority of the samples were males: 74 (68.5%),
compared to females: 34 (31.5%). Out of the 108 cohort, 54
cases  were  confirmedly  diagnosed  as  PEG  cases,  while
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glaucoma by examination, served as controls (see Methods
for inclusion and exclusion criteria). The gender constitution
of  both  patients  and  controls  was  exactly  matching:  37
(68.5%) males and 17 (31.5%) females. Meanwhile, the mean
(±SD) age of both cases and controls were: 67.6 (10.4), range
33–83, and 67.7 (10.6), range 32–85, respectively, which did
not statistically differ (p=0.942). However, the mean total
antioxidant  (TAS)  value  was  lower  among  patients:  0.87
(0.241), range 0.9–1.41 than controls: 1.07 (0.234), range
0.72–1.94, where this difference was statistically significant
(p<0.0001: 95% CI: −0.295–0.114; Table 2).
Disaggregating these data by gender yielded no apparent
difference between males and females either among cases or
controls. This suggests that gender probably does not play a
role in the average antioxidant value (Table 3).
As for SNP rs1048661 (g.5758 G>T) among patients, 43
(79.6%) individuals were of genotype G/G, while 11 (20.4%)
were  of  genotype  G/T.  As  for  the  controls,  31  (57.4%)
individuals had the genotype G/G, 21 (38.9%) had the G/T
TABLE 1. PRIMERS USED IN THE STUDY.
Exon Primer Sequence Annealing
Temp. (°C)
Amplicon
Size (bp)
Promoter-F TGTAAAACGACGGCCAGTAGGGACTGAGGGAGCACT 60 465
Promoter-R CAGGAAACAGCTATGACCAGCCATGGTGACCCCTCT    
1A-F TGTAAAACGACGGCCAGTTCCCAGCCTGTTGCTTATTC 60 789
1A-R CAGGAAACAGCTATGACCGTTGCTGGGAGACGGAGGT    
1B-F TGTAAAACGACGGCCAGTATTCGGCTTTGGCCAGGT 60 810
1B-R CAGGAAACAGCTATGACCCCGGAGCAGTTTCCAGTG    
1C-F• TGTAAAACGACGGCCAGTGCTCAACTCGGGCTCAGA 57 553
1C-R• CAGGAAACAGCTATGACCCGCCGTACTCCTCGTAGC    
2-F TGTAAAACGACGGCCAGTTGCTCTCAATGTCATGCTCTT 60 209
2-R CAGGAAACAGCTATGACCCGGGGACTATCCCAACACT    
3-F TGTAAAACGACGGCCAGTGTGTCACTGTGCCCCAACC 60 232
3-R CAGGAAACAGCTATGACCCCCAGAGGAGAAGTGGAAGA    
4-F TGTAAAACGACGGCCAGTGAGAGGCCCAGGGAAGACTA 58 265
4-R CAGGAAACAGCTATGACCCCTCCCCAACTCCTTATCCT    
5-F TGTAAAACGACGGCCAGTGGGGTGGCTCTGGGAAAC 58 210
5-R CAGGAAACAGCTATGACCGGGGGACATTGGACATGA    
6-F TGTAAAACGACGGCCAGTCCCCTGACTAGACTCCCTTTC 60 234
6-R CAGGAAACAGCTATGACCGTATCTCAGGTGGCCTTGC    
7-F TGTAAAACGACGGCCAGTCTACTTTGCAGCCCCTCATT 60 410
7-R CAGGAAACAGCTATGACCCCAGGCCCAAACTAGCTG    
        F: Forward; R: Reverse; •SNPs rs1048661 and rs3825942 were amplified with this primers set. Bold and underlined sequences
        are those of the M13.
TABLE 2. DEMOGRAPHIC CHARACTERISTICS AND TAS LEVEL OF BOTH CASES AND CONTROLS
Number n=54 n=54 p-value
M/F 37/17 37/17  
Age (years) 67.72 (10.60) 67.57 (10.43) 0.9418
TAS (mmol/l) 1.07 (0.234) 0.866 (0.241) <0.0001
        Values are expressed as mean±standard deviation (SD). P-values are determined by unpaired Student’s t-test. M – male: F –
         female: TAS – total antioxidant levels.
TABLE 3. MEAN TAS VALUE BY GENDER AMONG CASES AND CONTROLS.
Gender Patients Controls
Male
Mean (SD) 0.849 (0.26) 1.1 (0.25)
Range [min–max] [0.09–1.41] [0.72–1.94]
Female
Mean (SD) 0.9 (0.20) 0.99 (0.18)
Range [min–max] [0.37–1.18] [0.78–1.4]
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2771genotype,  while  two  cases  (3.7%)  had  the  T/T  genotype.
Within each group, the mean TAS value also varied across
different categories, however insignificantly (p-values within
patients and controls were: 0.373 and 0.808, respectively).
Within  cases,  53  (98.1%)  of  patients  had  the  G/G
genotype, while only one case (1.9%) had G/A. Alternatively,
among controls, 46 (85.2%) had G/G and eight (14.8%) had
G/A. Although it was not possible to compare mean values of
TAS among cases with different genotypes, comparing mean
TAS among different categories of controls showed that the
apparently  slight  difference  is  not  statistically  significant
(p=0.922).
Consequently, comparing cases with the G/G genotype
to  controls  with  the  G/G  genotype,  there  was  a  highly
significant difference between the two groups in terms of the
mean  TAS  value:  0.049  (p<0.0001).  However,  when  we
compared cases with G/T genotype to controls with the same
genotype, there was no difference (p=0.131; Table 4).
As for SNP rs3825942 (g.5758 G>A) among patients, 53
(98.1%) individuals were of genotype G/G, while only one
case (1.9%) had G/A. Among controls, 46 (85.2%) had G/G
and eight (14.8%) had G/A. Although it was not possible to
compare mean values of TAS among cases with different
mutations, comparing mean TAS among different categories
of controls showed that the apparently slight difference is not
statistically significant (p=0.922). Alternatively, comparing
patients with G/G to controls with G/G, there was a highly
significant difference between the two groups in terms of the
mean TAS value (p<0.0001; Table 5).
With the aim of evaluating the impact of age, sex, and the
mutation, in addition to the mean TAS value in patients with
pseudoexfoliation,  a  logistic  regression  analysis  was
conducted  using  diseased/not  diseased  as  the  outcome  of
interest  (the  dependent  variable).  Results  show  that,
controlling  for  all  other  variables,  mean  TAS  value
(p<0.0001) and the mutation G/G in rs3825942 (p=0.041) are
significant risk factors for PEG.
DISCUSSION
We obtained plasma samples from 54 extensively diagnosed
PEG patients and 54 controls. Our control group was carefully
selected in terms of age, sex, and ethnicity. We established
that  there  were  free  of  glaucoma  by  extensive  clinical
examination. Selecting the control group with age and sex
matching to the patient group was of particular importance, as
those factors can influence the TAS level, and thus can affect
the  results  independent  of  the  glaucoma  status  [22].  The
results obtained here demonstrated a marked decrease in TAS
in PEG patients compared to controls. The literature shows
inconsistent findings regarding antioxidant activity in serum
and  aqueous  humor  in  glaucoma  patients.  Yildrim  and
colleagues [23] studied 40 patients with glaucoma and found
TABLE 4. MEAN TAS VALUE BY RS1048661 CATEGORY AMONG CASES AND CONTROLS.
Genotype Case Control p value
G/G
Mean (SD) 0.857 (0.24) 1.089 (0.27) <0.0001
Range [min–max] [0.09–1.41] [0.72–1.94]  
G/T
Mean (SD) 0.897 (0.26) 1.054 (0.178) 0.131
Range [min–max] [0.37–1.18] [0.76–1.45]  
T/T
Mean (SD) NA 0.95 (0.071) -
Range [min–max]   [0.9–1]  
               P-values are determined by Mann–Whitney U test.
TABLE 5. MEAN TAS VALUE BY RS3825942 CATEGORY AMONG CASES AND CONTROLS.
Genotype Case Control p-value
G/G
Mean (SD) 0.864 (0.24) 1.075 (0.25) <0.0001
Range [min-max] [0.09–1.41] [0.72–1.94]  
G/A
Mean (SD) NA 1.039 (0.10) -
Range [min-max]   [0.89–1.18]  
               P-values are determined by Mann–Whitney U test.
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2772no  association  between  glaucoma  and  systemic
myeloperoxidase  or  catalase  enzyme  activity.  Yuki  and
colleagues  [24]  found  an  increase  in  the  serum  total
antioxidant status of patients with normal-tension glaucoma
compared to matching controls. In contrast, Sorkhabi et al.
[25] showed that the serum level of TAS in patients with
primary open angle glaucoma was lower than that of cataract
controls.  Gherghel  and  colleagues  [26]  concluded  that
glaucoma  patients  exhibit  low  levels  of  circulating
glutathione, suggesting compromised oxidative defense. The
only study of total reactive antioxidant potential (TRAP) and
antioxidant enzymes in aqueous humor was performed by
Ferreira and colleagues, and showed significantly decreased
TRAP  values  and  increased  superoxide  dismutase  and
glutathione peroxidase activity in glaucoma patients [27]. An
antioxidant is by definition any substance that, when present
at low concentration compared with those of an oxidizable
substrate, significantly delays or prevents oxidation of that
substrate. The antioxidant defense system comprises a variety
of  molecules:  enzymes  such  as  superoxide  dismutase,
catalase,  or  glutathione  peroxidase  that  are  capable  of
catalytically removing free radicals and other reactive species;
proteins, such as transferrins or haptoglobins, that minimize
the availability of pro-oxidants such as iron or copper ions;
heat shock proteins that protect biomolecules against damage;
and  low-molecular  mass  molecules  such  as  α-tocopherol,
ascorbic acid, or glutathione capable of scavenging ROS and
RNS. The composition of antioxidant defenses differs from
tissue to tissue and from cell type to cell type [28]. All of these
compounds and more exist in human plasma. Antioxidants
that  can  be  found  in  human  plasma  vary,  and  can  be
summarized mainly in the following compounds: albumin,
ceruloplasmin,  ferritin,  ascorbic  acid,  α-tocopherol,  β-
carotene,  lycopene,  reduced  glutathione,  bilirubin,
glutathione peroxidase, uric acid, catalase, and superoxide
dismutase [29]. The exact mechanism of how oxidative stress
contributes to glaucoma pathogenesis remains speculative.
Glaucomatous  optic  neuropathy  implies  loss  of  retinal
ganglion  cells,  including  their  axons,  and  a  major  tissue
remodeling,  especially  in  the  optic  nerve  head.  Although
increased  intraocular  pressure  is  a  major  risk  factor  for
glaucomatous optic neuropathy, there is little doubt that other
factors such as ocular blood flow play a role as well [30].
Mechanisms leading to glaucomatous optic neuropathy are
not  yet  clearly  understood.  There  is,  however,  increasing
evidence that both an activation of glial cells and oxidative
stress in the axons may play an important role [31]. Glial cells
may be activated by mechanical stress via activation of the
epidermal growth-factor receptor, or by ischemic stress via an
increase in endothelin. Several factors can systemically or
locally increase oxidative stress. In glaucoma, an unstable
ocular blood flow leading to repeated mild reperfusion seems
to  be  most  relevant  in  inducing  oxidative  stress.  The
simultaneous production of nitric oxide in the astrocytes and
of superoxide in the mitochondria of the axons leads to the
production  of  the  damaging  peroxynitrite  [32].
Therapeutically,  we  need  to  reduce  intraocular  pressure,
stabilize ocular blood flow, and reduce oxidative stress. The
fact that the mean total antioxidants were reduced in PEG
patients  compared  to  age-,  sex-,  and  ethnicity-matched
healthy controls certainly contributes to the creation of an
oxidative stress status and, in such a mechanism as described
above,  such  a  situation  may  contribute  to  glaucoma
pathogenesis.
Our total antioxidants method employed here measured
the total antioxidant status and not a particular compound or
byproduct.  A  detailed  examination  of  those  individual
antioxidants separately might help to identify a particular
antioxidant that is severely decreased and thus provide a new
therapeutic agent for glaucoma. We have to acknowledge that
the systemic decrease in antioxidants might not reflect the
exact situation at the anterior segment structures, which are
exposed to free radicals and thus more directly involved in the
formation  and  development  of  glaucoma  through  the
oxidative stress mechanism.
We recently shown that the “G” allele frequencies of both
rs1048661 and rs3825942 SNPs of LOXL1 differed between
pseudoexofoliation  glaucoma  (PEG)  patients  and  control
subjects  from  Saudi  Arabia  (p=0.0056  and  p<0.0001,
respectively)  [21].  These  results  were  in  agreement  with
previous similar studies in various populations. When we
compared cases with the G/G genotypes (for both LOXL1
SNPs) to controls with the same genotype, it was clear that
there was a highly significant difference between the two
groups in terms of the mean TAS value. To the best of our
knowledge this is the first time the combined effect of the TAS
and  the  LOXL1  PEG-risk  SNPs  was  investigated.  The
mechanism  by  which  these  SNPs  may  play  a  role  in  the
development  of  PEG  is  quite  different  from  that  of  the
oxidative  stress  mechanism  suggested  here  as  a  result  of
decreased  TAS.  LOXL1  belongs  to  a  group  of  proteins
responsible for catalyzing the oxidative deamination of lysine
residues of tropoelastin (summarized by Hewitt et al. [33]). In
turn, this deamination causes spontaneous cross-linking and
formation  of  elastin  polymer  fibers.  Thus,  mutations  in
LOXL1 are expected to affect elastin formation. Loss of elastin
in turn causes iridolenticular friction, which leads to loss of
exfoliation material (XFM) from the anterior lens surface and
disruption of the iris pigment epithelium, resulting in pigment
deposition in the trabecular meshwork, which also produces
XFM locally. The primary cause of chronic pressure elevation
appears to be the active involvement of trabecular cells. Thus
it is clearly a different mechanism from the proposed oxidative
stress indicated by the decreased level of total antioxidants
reported here.
In summary, our findings report a TAS decrease in the
plasma of PEG patients and suggest that TAS may have an
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2773important role in the pathogenesis of glaucoma. The combined
effect  of  the  “G”  allele  and  the  decreased  TAS  clearly
contribute to the development of PEG, but through different
mechanisms,  one  mechanism  through  LOXL1  and  the
resultant  iridolenticular  friction,  and  the  other  through
oxidative stress marked by decreased TAS.
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